BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
MRK upcoming catalysts
Merck Sharp & Dohme LLC: 7 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (4 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 32 readout(s) and 19 FDA event(s). Subscribe to MRK (.ics).
Drugs: Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Tulisokibart, Paclitaxel, Cisplatin, Favezelimab/Pembrolizumab, Docetaxel, Gemcitabine, etoposide, Sacituzumab tirumotecan, Irinotecan, Carboplatin, Palbociclib, Sacituzumab Govitecan, Fluorouracil, Mitomycin C, doxorubicin, vinblastine, dacarbazine, cyclophosphamide, vincristine, prednisone/prednisolone, bleomycin, Trifluridine-Tipiracil, Methotrexate, Rosuvastatin, durvalumab, pemetrexed, Olaparib, nab-paclitaxel, capecitabine
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer | Endometrial Neoplasms | active not recruiting | 990 |
| 2026-12-22 est. | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT05468697 A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LI | Renal Cell Carcinoma | active not recruiting | 60 |
| 2027-01-12 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT05609968 Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung | Carcinoma, Non-Small-Cell Lung | active not recruiting | 614 |
| 2027-01-15 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04199689 Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | Papillomavirus Infections | active not recruiting | 6033 |
| 2027-01-31 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99 | Urinary Bladder Neoplasms | active not recruiting | 520 |
| 2027-02-12 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | Hodgkin Lymphoma | active not recruiting | 340 |
| 2027-02-17 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT07486960 Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) | Psoriatic Arthritis | active not recruiting | 140 |
FDA decision events, last 12 months
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-28 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT05239728 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrec | Carcinoma, Renal Cell | active not recruiting | 1800 |
| 2026-10-19 | P3 | Merck Sharp & Dohme LLC MRK | NCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Gastroesophageal Cancer | active not recruiting | 473 |
| 2026-09-30 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT06637423 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | Non-Muscle Invasive Bladder Cancer | completed | 35 |
| 2026-09-07 | P2 | Merck Sharp & Dohme LLC MRK | NCT07176390 A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) | Arthritis, Rheumatoid | active not recruiting | 185 |
| 2026-08-18 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT06864169 A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) | Gastrointestinal Cancer | active not recruiting | 160 |
| 2026-08-12 | P3 | Merck Sharp & Dohme LLC MRK | NCT06052059 A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) | Ulcerative Colitis | active not recruiting | 1109 |
| 2026-08-10 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04626479 Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | Carcinoma, Renal Cell | completed | 393 |
| 2026-08-03 | P3 | Merck Sharp & Dohme LLC MRK | NCT07216482 A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) | Hyperlipidemia | completed | 996 |
| 2026-08-03 | P2 | Merck Sharp & Dohme LLC MRK | NCT06465186 A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD; Metabolic Dysfunction-associ | completed | 85 |
| 2026-07-23 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | Carcinoma, Renal Cell | completed | 263 |
| 2026-06-15 | P3 | Merck Sharp & Dohme LLC MRK | NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemora | Carcinoma, Non-Small-Cell Lung | completed | 610 |
| 2026-06-08 | P2 | Merck Sharp & Dohme LLC MRK | NCT04123366 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Re | Solid Tumors | completed | 333 |
| 2026-06-05 | P2 | Merck Sharp & Dohme LLC MRK | NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) | Alzheimer Disease; Dementia | terminated | 369 |
| 2026-05-18 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04305054 Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanc | Melanoma | completed | 335 |
| 2026-04-24 | P3 | Merck Sharp & Dohme LLC MRK | NCT04895358 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3 | Breast Neoplasms | active not recruiting | 342 |
| 2026-04-21 | P2 | Merck Sharp & Dohme LLC MRK | NCT05144841 A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | 140 |
| 2026-04-09 | P2 | Merck Sharp & Dohme LLC MRK | NCT05612035 Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD | Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease | active not recruiting | 129 |
| 2026-04-02 | P2 | Merck Sharp & Dohme LLC MRK | NCT06956235 Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) | Hidradenitis Suppurativa | active not recruiting | 149 |
| 2026-03-12 | P3 | Merck Sharp & Dohme LLC MRK | NCT06698042 A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | Lung Cancer; Non-Small Cell Lung Cancer | active not recruiting | 67 |
| 2026-03-12 | P2 | Merck Sharp & Dohme LLC MRK | NCT06036836 Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | Solid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer | completed | 163 |
| 2026-03-05 | P2/P3 | Merck Sharp & Dohme LLC MRK | NCT06295809 A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) | Carcinoma, Squamous Cell; Skin Neoplasms | terminated | 46 |
| 2026-02-04 | P3 | Merck Sharp & Dohme LLC MRK | NCT05899049 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination Wit | Carcinoma, Renal Cell | active not recruiting | 251 |
| 2026-02-04 | P3 | Merck Sharp & Dohme LLC MRK | NCT04736706 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination Wit | Carcinoma, Renal Cell | active not recruiting | 1688 |
| 2026-02-02 | P3 | Merck Sharp & Dohme LLC MRK | NCT04586231 A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | Carcinoma, Renal Cell | active not recruiting | 747 |
| 2026-01-28 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT03598608 Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (M | Hodgkin Disease; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell | terminated | 137 |
| 2026-01-26 | P3 | Merck Sharp & Dohme LLC MRK | NCT03924856 Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-inv | Bladder Cancer | completed | 907 |
| 2026-01-21 | P3 | Merck Sharp & Dohme LLC MRK | NCT04210115 Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYN | Esophageal Squamous Cell Carcinoma (ESCC); Gastroesophageal Junction Carcinoma (GEJC); Esophageal Ad | completed | 703 |
| 2026-01-14 | P3 | Merck Sharp & Dohme LLC MRK | NCT02684292 Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) | Hodgkin Lymphoma | completed | 304 |
| 2025-12-29 | P2 | Merck Sharp & Dohme LLC MRK | NCT05877547 A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Diseas | completed | 381 |
| 2025-12-22 | P3 | Merck Sharp & Dohme LLC MRK | NCT04193215 V114 and Acute Otitis Media (V114-032/PNEU-ERA) | Acute Otitis Media (AOM) | completed | 7119 |
| 2025-12-05 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT05342636 A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | Esophageal Squamous Cell Carcinoma (ESCC) | completed | 90 |
| 2025-11-20 | P2 | Merck Sharp & Dohme LLC MRK | NCT06664801 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) | Pulmonary Arterial Hypertension | completed | 164 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.